September 26. 2006

• Special Warnings with Telithromycin (KETEK)
  The manufacturer of telithromycin (KETEK) revised its warning label. The update contains warning on acute hepatic failure and severe liver injury.

September 25. 2006

• Levofloxacin-based triple therapy effective first-line treatment for H. pylori eradication
• Levofloxacin-ceftazidime combination effective against hospital-acquired pneumonia in ICU patients

September 19. 2006

• FDA has concerns about expanding use of Gemifloxacin (FACTIVE)
  Gemifloxacin (FACTIVE), proposed as a treatment for acute sinus infections, should be studied further due to serious skin reactions associated with its use according to FDA documents released on Sep 12, 2006.
• Japanese study shows that levofloxacin activity remains stable over a 13 year period
• Re-treatment therapy of Helicobacter pylori involving levofloxacin is very successful

September 11. 2006

• Majority of dysentery pathogens remain susceptible to levofloxacin and other fluoroquinolones in China

September 4. 2006

• Latest data from the SENTRY surveillance program shows levofloxacin remains highly effective against H. influenzae
• Magnesium complexes of ofloxacin and levofloxacin have similar antimicrobial activity to the parent drugs

Return to 2006 Archive